Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q1 2025 · 10-Q
Revenue$87.12M$87.12M+39.6% vs Q1 2024 Net Income-$6.53M-$6.53MN/M vs Q1 2024 EPS Diluted-$0.23-$0.23N/M vs Q1 2024 Gross Profit$58,476,000+56.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flow$10,182,000N/M Free Cash Flowderived$4,053,000N/M Margins · derivedGross margin67.1%+7.2 pt vs Q1 2024
Operating margin-5.2%+16.7 pt vs Q1 2024
Net margin-7.5%+24.9 pt vs Q1 2024
ended Mar 31, 2025 · filed Apr 30, 2025 · 30 d after period end